Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Open-market buy Director bought 27,708 shares at $1.69 ($46,827)
  4. 4 Open-market buy Director bought 47,160 shares at an average $1.48 ($69,694)
  5. 4 Open-market buy Director bought 175,132 shares at an average $1.47 ($256,970)
  6. 4 Other disposition Director disposed of 2,500,000 shares (other)
  7. 4 Other acquisition Director acquired 2,500,000 shares (other)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market buy CEO and President bought 25,000 shares at $1.39 ($34,750)
  11. 4 Open-market buy Chief Operating Officer bought 25,201 shares at $1.38 ($34,777)
  12. 4 Open-market buy Chief Commercial Officer bought 35,200 shares at $1.34 ($47,168)
  13. 4 Open-market buy Chief Operating Officer bought 10,000 shares at $1.42 ($14,200)
  14. 4 Open-market buy Director bought 10,000 shares at $1.39 ($13,900)
  15. 4 Open-market buy Director bought 18,000 shares at $1.40 ($25,200)
  16. 4 Open-market buy CEO and President bought 10,000 shares at $1.40 ($14,000)
  17. 4 Open-market buy Director bought 16,000,000 shares at $1.25 ($20,000,000)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 6 of 16 · 305 filings